Easton Pharmaceuticals Inc. (OTC:EAPH) is pleased to announce that revenue generating operations have commenced on its Alliance Group property and businesses.
Easton’s JV partner, 1124123 Ontario Limited (o/a – Alliance Group) is pleased to announce that revenues have commenced on its Georgina property, located just north of Toronto, Ontario, Canada. After delays resulting from various factors including poor early spring weather conditions, heavy machinery having a value in excess of $2 million were delivered to the property which resulted with the commencement of operations last week with revenues in excess of $20,000 in its first 2 days.
This revenue marks the beginning of several business segments that will be carried out from the property. The first business is soil, while the company is gearing up for operations to soon commence from its aggregate business and marijuana production.
Easton Pharmaceuticals and Alliance Group will be providing many more detailed updates in the coming weeks on revenue generation and future projections which can now be booked on Easton’s financial statements. Other future updates will include updates / changes to existing / new acquisitions and businesses, changes and new additions to its management team, Easton moving forward with Alliances medical / recreational marijuana operations as well as moving forward with audited financial statements and its retaining of an auditor now that revenues have commenced with Alliance Group and the expected revenues from Easton / BMV Medica’s sub-distribution Agreement recently executed with BAYER and the legal entity for its subsidiary company, BAYER Consumer Care for its woman’s diagnostic product known as VS-Sense for the country of Mexico.
Easton Pharmaceuticals executed an agreement with 1124123 Ontario Limited (o/a – Alliance Group) in June of 2017 where it advanced $1.3 million in Canadian currency to Alliance Group towards property and several businesses. Easton is pleased to have demonstrated that this investment and partnership with Alliance is now starting to generate revenues as planned when it entered into the transaction and is expecting substantial revenue based on commitments received to date.
<b>About Easton Pharmaceuticals</b>
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing medical drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has partnered with BMV Medica S.A. and together own the exclusive distribution rights in Mexico and Latin America for two patented women’s diagnostic products and a novel natural treatment for Bacterial Vaginosis. In addition, a generic cancer drug line is being developed for sale in Mexico. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs and Cannabinoid extracts.
For More Information On Easton Pharmaceuticals Visit:
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope”, “positive”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.
CONTACT INFORMATIONInvestor RelationsTel: +1(416) 619-0291Tel: +1(347) 284-0192Email: firstname.lastname@example.org
<img src=”http://www.globenewswire.com/newsroom/ti?ndecode=MTUwIzcyOTc5NDA=” alt=”” width=”1″ height=”1″/>